ACP endorses use of PDE5 inhibitors for ED

The American College of Physicians (ACP) has just issued new guidelines that strongly endorses use of sildenafil (Viagra) and similar drugs for the treatment of erectile dysfunction (ED).

While the use of the PDE5 inhibitors (sidenafil, tadalifil/Cialis, and vardenifil/Levitra) for the treatment of ED in patients who have received treatment for prostate cancer is significantly less effective than in patients who have simple ED, this endorsement of the drugs as effective and safe by one of the most influential groups of primary care physicians may help to lead to a greater willingness by insurance providers to cover the use of these drugs in patients with a clear medical need (prostate cancer patients included).

The full guideline is available on the web site of the Annals of Internal Medicine, and will be published in the November issue of the journal. A media release and video commentary can be found on the web site of the American College of Physicians.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: